36 related articles for article (PubMed ID: 35666594)
1. Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.
Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
Drugs; 2024 May; ():. PubMed ID: 38739333
[No Abstract] [Full Text] [Related]
2. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated
Yaeger R; Weiss J; Pelster MS; Spira AI; Barve M; Ou SI; Leal TA; Bekaii-Saab TS; Paweletz CP; Heavey GA; Christensen JG; Velastegui K; Kheoh T; Der-Torossian H; Klempner SJ
N Engl J Med; 2023 Jan; 388(1):44-54. PubMed ID: 36546659
[TBL] [Abstract][Full Text] [Related]
3. Adagrasib: a novel inhibitor for
Guo MZ; Marrone KA; Spira A; Rosner S
Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
[TBL] [Abstract][Full Text] [Related]
4. Adagrasib: First Approval.
Dhillon S
Drugs; 2023 Feb; 83(3):275-285. PubMed ID: 36763320
[TBL] [Abstract][Full Text] [Related]
5. Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.
Yin G; Huang J; Petela J; Jiang H; Zhang Y; Gong S; Wu J; Liu B; Shi J; Gao Y
Signal Transduct Target Ther; 2023 May; 8(1):212. PubMed ID: 37221195
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of KRAS
Sisler DJ; Hinz TK; Le AT; Kleczko EK; Nemenoff RA; Heasley LE
Front Oncol; 2023; 13():1094123. PubMed ID: 36845684
[TBL] [Abstract][Full Text] [Related]
7. Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
Zhang J; Johnson M; Barve M; Bazhenova L; McCarthy M; Schwartz R; Horvath-Walsh E; Velastegui K; Qian C; Spira A
Oncologist; 2023 Apr; 28(4):287-296. PubMed ID: 36892150
[TBL] [Abstract][Full Text] [Related]
8.
Ceddia S; Landi L; Cappuzzo F
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
[No Abstract] [Full Text] [Related]
9. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
[TBL] [Abstract][Full Text] [Related]
10. Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases.
Kommalapati A; Mansfield AS
Clin Cancer Res; 2022 Aug; 28(15):3179-3181. PubMed ID: 35608481
[TBL] [Abstract][Full Text] [Related]
11. Adagrasib in Non-Small-Cell Lung Cancer Harboring a
Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI
N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005
[TBL] [Abstract][Full Text] [Related]
12. Adagrasib's Efficacy Sustained in KRASG12C NSCLC.
Cancer Discov; 2023 Nov; 13(11):OF1. PubMed ID: 37702568
[TBL] [Abstract][Full Text] [Related]
13. Safety and Intracranial Activity of Adagrasib in Patients With
Bernstein E; Luo J; Wang K; Negrao MV; Jänne PA; Sabari JK
JCO Precis Oncol; 2024 Feb; 8():e2300447. PubMed ID: 38330263
[No Abstract] [Full Text] [Related]
14. Adagrasib Response Remains Strong in NSCLC.
Cancer Discov; 2022 Aug; 12(8):OF1. PubMed ID: 35666594
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
